Psilocybin-Induced Neuroplasticity in the Treatment of Major Depression
Purpose: This study will investigate neurobiological and psychological effects of psilocybin-assisted therapy in people with major depressive disorder. The primary hypothesis is that psilocybin administered in a therapeutic context will result in neuroplastic changes that parallel improvement in symptoms of depression.
- Patients with current moderate to severe major depressive disorder despite one adequate antidepressant trial
- Engaged in treatment with a mental health provider
- To participate, patients will need to be off psychiatric medications (e.g.,SSRIs) that may alter the effects of psilocybin (providers can discuss this with study physicians).
Major exclusions include: Uncontrolled medical and neurological conditions, history of psychotic disorders or bipolar disorders in participant or first degree relatives, active substance abuse disorder.
- Approximately16 weeks of study participation
- Two experimental sessions approximately four weeks apart during which participants will receive two of the following three interventions: 1) placebo, 2) low dose psilocybin, and 3) medium-high dose psilocybin
- Experimental sessions will be embedded within a psychotherapeutic framework consisting of eight preparatory, debriefing, and follow-up sessions with trained psychotherapists.
- Electroencephalographic (EEG) data will be collected at four time points to assess changes in neuroplasticity.
Compensation: Subjects can receive up to $350 for participating in this study
For More Information about Study Participation:
- Dr. Deepak Cyril D'Souza (Principal Investigator)
- Surbhi Pathania (Research Coordinator)
- Dr. Jordan Sloshower (Co-investigator)
This study is now closed for new enrollment as of 8-3-21. Contact the Behavioral Wellness Clinic for new studies and options.
More information about this clinical trial of psilocybin-assisted therapy for depression: www.clinicaltrials.gov/ct2/show/NCT03554174.